Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

In the Media

  • November 13, 2018

Cannabinoid-based Therapeutics: Terpenes and Testing Magazine

Looking through the Telescope onto the Horizon: InMed Pharmaceuticals

Nearly every week, there is another cannabis-themed headline such as “New Study Says 97% of Elderly Patients Say Cannabis Makes Them Feel Better, Decrease Prescription Meds”. [1] While multitudes of people are turning to cannabis to treat everything from anxiety, post-traumatic stress disorder, glaucoma, or other all-to-common ailments like pain, there are sufferers of conditions so debilitating, that they are in need of anything that works. Available treatments may include a litany of prescription drugs, often with deleterious side effects of their own, which might help one problem, while creating another. And while scores of people will tout that indicas will help you sleep, or that sativas will help you energize, who’s out there looking farther onto the horizon, and deeper into cannabis’s full potential using proven science through pharmaceutical-grade R&D efforts

InMed Pharmaceuticals represents one company in search of something deeper and certainly more impactful than what will or will not give you couch-lock. Rather, InMed strives to mine the most out of cannabinoid-based therapeutics without actually having to cultivate anything. And they are creating novel cannabinoid formulations meant to treat extremely painful, incapacitating medical conditions.

I spoke with Eric A. Adams, the Chief Executive Officer of InMed Pharmaceuticals, a bio-pharmaceutical company based in Vancouver, British Columbia. The four-year old company specializes in generating therapeutic products designed from cannabinoids. That’s not to say the company is actively growing cannabis plants, however. “We don’t work with the plant,” Adams explained. “And there’s no THC in any of our products. We believe that there are more active cannabinoids than THC in the cannabis plant.”

And this is exactly why InMed cannot simply grow cannabis. Since they are not working with THC, the levels of the cannabinoids they seek are just too low in the natural plant. So, InMed prepares their formulations from biosynthesized cannabinoid compounds. Thus, they are developing a technology to make all the cannabinoids they need at a fairly low cost. “We never need to grow a single plant. Essentially, we’re borrowing from other medical areas, such as insulin production,” Adams explained. To do this, the genes for cannabinoid production are inserted into Escherichia coli, a bacterium which in turn produces the cannabinoid of interest. This is a similar process to inserting the gene into yeast; however, InMed has found it more cost effective to use the bacteria.

InMed, to date, has been a company that has thrived in creating topical cannabinoid formulations. Like other companies, capitalizing on the increasingly lessened restrictions on cannabis R&D, InMed has been focused on designing products meant to go through governmental organizations like the US Food and Drug Administration, or HealthCanada. “We’ve been preparing products containing two cannabinoids. We’ve also been evaluating different mechanisms of action, and are looking at a host of other receptors throughout the body,” Adams added.

 

Full Article
Source: Terpenes and Testing Magazine, by Jason S. Lupoi, PhD

Share this post

Latest Articles

What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should

Read More
August 18, 2023

What makes cannabinoids an interesting pharmaceutical target?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the role of the endocannabinoid system? How do cannabinoids interact with the

Read More
August 18, 2023

What is the difference between illegal synthetics and bioidentical synthesized cannabinoids?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What are illegal synthetic cannabinoids? How are illegal synthetic cannabinoids different from bioidentical synthesized

Read More
July 18, 2023
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • INM-900 Series for Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*